Bleichmar Fonti & Auld LLP Files Lawsuit Against Hims & Hers Health Executives.
ByAinvest
Saturday, Jul 12, 2025 7:38 am ET1min read
HIMS--
The lawsuit, filed in the U.S. District Court for the Northern District of California, alleges that Hims & Hers made false statements and concealed material information regarding its collaboration with Novo Nordisk. Specifically, the complaint asserts that Hims & Hers misrepresented the nature of its partnership with Novo Nordisk, claiming it could offer both Wegovy and compounded semaglutide to its customers. It is also alleged that Hims & Hers represented to investors that its sale of compounded semaglutide complied with FDA regulations, which was not the case [1].
On June 23, 2025, Novo Nordisk announced the termination of the partnership due to Hims & Hers' alleged deceptive promotion and selling of illegitimate, knockoff versions of Wegovy, which put patient safety at risk. This revelation led to a significant drop in Hims & Hers' stock price, declining by more than 34% from $64.22 to $41.98 per share [1].
Investors who suffered losses during the relevant time frame are urged to contact Bleichmar Fonti & Auld LLP by August 25, 2025, to request the appointment of a lead plaintiff. The firm will represent investors on a contingency fee basis, with no out-of-pocket costs or expenses [1].
Bleichmar Fonti & Auld LLP is a leading international law firm with a track record of representing plaintiffs in securities class actions and shareholder litigation. The firm has recovered over $900 million in value from Tesla, Inc. and $420 million from Teva Pharmaceutical Ind. Ltd. [1].
References:
[1] https://www.globenewswire.com/news-release/2025/07/08/3111773/0/en/HIMS-NOTICE-Hims-Hers-Health-Inc-Shareholders-are-Notified-of-the-Pending-Class-Action-Lawsuit-Contact-BFA-Law-by-August-25-Court-Deadline-NYSE-HIMS.html
NVO--
TEVA--
TSLA--
A securities law firm, Bleichmar Fonti & Auld LLP, has filed a lawsuit against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws. Investors who purchased Hims & Hers securities are encouraged to visit the firm's website for more information. A lead plaintiff must be appointed by August 25, 2025, in the U.S. District Court for the Northern District of California.
NEW YORK, July 02, 2025 — Leading securities law firm Bleichmar Fonti & Auld LLP has filed a lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) and its senior executives for potential violations of federal securities laws. Investors who purchased Hims & Hers securities are encouraged to visit the firm's website for more information.The lawsuit, filed in the U.S. District Court for the Northern District of California, alleges that Hims & Hers made false statements and concealed material information regarding its collaboration with Novo Nordisk. Specifically, the complaint asserts that Hims & Hers misrepresented the nature of its partnership with Novo Nordisk, claiming it could offer both Wegovy and compounded semaglutide to its customers. It is also alleged that Hims & Hers represented to investors that its sale of compounded semaglutide complied with FDA regulations, which was not the case [1].
On June 23, 2025, Novo Nordisk announced the termination of the partnership due to Hims & Hers' alleged deceptive promotion and selling of illegitimate, knockoff versions of Wegovy, which put patient safety at risk. This revelation led to a significant drop in Hims & Hers' stock price, declining by more than 34% from $64.22 to $41.98 per share [1].
Investors who suffered losses during the relevant time frame are urged to contact Bleichmar Fonti & Auld LLP by August 25, 2025, to request the appointment of a lead plaintiff. The firm will represent investors on a contingency fee basis, with no out-of-pocket costs or expenses [1].
Bleichmar Fonti & Auld LLP is a leading international law firm with a track record of representing plaintiffs in securities class actions and shareholder litigation. The firm has recovered over $900 million in value from Tesla, Inc. and $420 million from Teva Pharmaceutical Ind. Ltd. [1].
References:
[1] https://www.globenewswire.com/news-release/2025/07/08/3111773/0/en/HIMS-NOTICE-Hims-Hers-Health-Inc-Shareholders-are-Notified-of-the-Pending-Class-Action-Lawsuit-Contact-BFA-Law-by-August-25-Court-Deadline-NYSE-HIMS.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet